Supernus Pharmaceuticals (SUPN) Downgraded by BidaskClub to Hold

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Wednesday.

Other analysts have also issued reports about the company. Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Piper Jaffray Companies reissued a “hold” rating and issued a $46.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, July 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. ValuEngine raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Finally, Jefferies Financial Group lifted their target price on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $54.78.

Shares of SUPN traded down $0.25 during midday trading on Wednesday, reaching $45.31. 2,066 shares of the company were exchanged, compared to its average volume of 587,493. The stock has a market cap of $2.17 billion, a PE ratio of 35.97 and a beta of 0.92. Supernus Pharmaceuticals has a 1-year low of $34.90 and a 1-year high of $61.25. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a return on equity of 32.22% and a net margin of 25.89%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 earnings per share. On average, research analysts anticipate that Supernus Pharmaceuticals will post 1.93 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. D.A. Davidson & CO. boosted its stake in Supernus Pharmaceuticals by 5.6% in the second quarter. D.A. Davidson & CO. now owns 17,369 shares of the specialty pharmaceutical company’s stock valued at $1,040,000 after acquiring an additional 921 shares during the period. Amalgamated Bank boosted its position in shares of Supernus Pharmaceuticals by 14.7% during the second quarter. Amalgamated Bank now owns 8,007 shares of the specialty pharmaceutical company’s stock worth $479,000 after buying an additional 1,028 shares during the period. First Republic Investment Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 10.3% during the second quarter. First Republic Investment Management Inc. now owns 12,572 shares of the specialty pharmaceutical company’s stock worth $753,000 after buying an additional 1,179 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after buying an additional 1,251 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Supernus Pharmaceuticals by 13.8% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,465 shares of the specialty pharmaceutical company’s stock worth $628,000 after buying an additional 1,509 shares during the period. Institutional investors own 99.10% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: What is a conference call?

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply